Thalidomide induced remission of refractory diffuse large B-Cell Lymphoma post-allogeneic SCT.

Haematologica ·Vol. 91 ·No. 6 Suppl ·2006-06-00 ·Pages ECR16

Tueger S, Chen FE, Ahsan G, McDonald V, Andrews VE, Madrigal JA, Kazmi MA

Abstract

Patients who relapse after High dose therapy and autologous stem cell transplant (ASCT) for Diffuse large B cell Lymphoma (DLBCL) have a poor prognosis with a median survival of only 3-6 month.1-2 This case demonstrates the ability of thalidomide at low doses to induce durable response in a patient with DLBCL who relapsed after full intensity allogeneic transplantation.

MeSH Terms

Adult Antineoplastic Agents/therapeutic use Combined Modality Therapy Humans Lymphoma, B-Cell/diagnostic imaging,drug therapy,therapy Lymphoma, Large B-Cell, Diffuse/diagnostic imaging,drug therapy,therapy Male Radiography Remission Induction Stem Cell Transplantation Thalidomide/therapeutic use Transplantation, Homologous

Chemicals

Antineoplastic Agents Thalidomide

Authors & Affiliations

7 authors, click to expand affiliations / ORCID

Tueger S

Dept. of Haematology, Guy's & St Thomas' NHS Foundation Trust, London, UK.

Chen F E

Ahsan G

McDonald V

Andrews V E

Madrigal J A

Kazmi M A

Article Info

Journal

Haematologica

Abbr.

Haematologica

ISSN

1592-8721

Published

2006-06-00

Pages

ECR16

Language

English

Region

Italy

NLM ID

0417435

Subset

External Links

PubMed source View journal details

Analysis Services

Thalidomide induced remission of refractory diffuse large B-Cell Lymphoma post-allogeneic SCT.

Contact

WeChat Official Account